Primary prostate tumours are inherently immune “cold” tumours and show: (1) low tumour mutation burden and low number of new neoantigens, (2) decreased or low levels of MHC class I and II in antigen‐presenting cells, (3) increased levels of myeloid‐derived suppressor cells, regulatory T cells, tumour‐associated macrophages and cancer‐associated fibroblasts and (4) an immunosuppressive cytokine profile enriched in TGF‐β.12 The gene discussed is TGFB1; the disease is cancer.